

Docket No.: H1890.0201/P201

(PATENT)

# IN THE UNITED STATES PATENT AND TRADEMARK OF CE

In re Patent Application of:

Gary D. Hodgen, et al.

Application No.: 09/313,628

Filed: May 18, 1999

For: CONTROL OF SELECTIVE ESTROGEN

RECEPTOR MODULATORS

Group Art Unit: 1617

Examiner: R. Travers

3 E 29/E Aform 8/19/95

### **SUBMISSION**

MS Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## **SUBMISSION**

This is a submission being filed in connection with an RCE. Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

#### **FEE CALCULATION**

Any additional fee required has been calculated as follows:

\_X\_ If checked, Small Entity status is claimed

72940 v1; 1K@401I.DOC

Application No.: 09/313,628 Docket No.: H1890.0201/P201

	No. Claims		Highest No.		Extra		Rate	Additional
	After		Previously		Present			Fee
	Amendment		Paid For					
Total	13	MINUS	33**	=	0	Х		\$
Indep.	1	MINUS	3**	=	0	Χ		\$
First presentation of multiple dependent claim(s)								\$
TOTAL							\$ -0-	

<sup>\*</sup> not less than 20

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-2215.

## CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. § 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. § 1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 50-2215.

<sup>\*\*</sup> not less than 3

Application No.: 09/313,628 Docket No.: H1890.0201/P201

## **SUMMARY OF AMENDMENTS**

# **SPECIFICATION**

<u>X</u>	There are no amendments to the specification.  Marked up replacement(s) paragraphs are presented in a separate section.				
CLAIMS					
	There are no amendments to the claims.				
X	A complete listing of all claims ever present in this case in				
asc	ending order with status identifier is presented in a separate section.				